Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial performance, with significant revenue and EPS growth, increased guidance, and positive market trends. Product development updates, especially for orforglipron, indicate potential future growth. The Q&A section reveals optimism about new product launches and market expansion, despite some unanswered questions about cash pay dynamics. The company's strategic reinvestments and shareholder returns further support a positive outlook, although the lack of specific guidance metrics and management's evasive responses slightly temper the sentiment.
Key Financial Performance
Full Year Revenue $65.2 billion, increased by 45% compared to 2024. The growth was driven by key products and new medicine launches.
Earnings Per Share (EPS) $24.21, grew by 86% compared to 2024. This was due to strong revenue growth and operational performance.
Q4 Revenue Increased by 43% compared to Q4 2024, driven by key products.
Gross Margin 83.2% of revenue, consistent with Q4 2024. Favorable product mix and improved production costs were offset by lower realized prices.
R&D Expenses Increased by 26% year-over-year, driven by continued investments in early and late-stage portfolio.
Marketing, Selling, and Administrative Expenses Increased by 29% year-over-year, driven by promotional efforts to support ongoing and future launches.
Non-GAAP Performance Margin 47.2%, an increase of 4.2 percentage points compared to Q4 2024.
Effective Tax Rate 19.7%.
Key Products Revenue Contribution Over $13 billion in Q4, grew by 91% compared to Q4 2024. Driven by products like Mounjaro, Zepbound, and others.
U.S. Revenue Increased by 43% in Q4, driven by volume growth of Mounjaro and Zepbound, partially offset by a 7% decline in price.
Revenue Outside the U.S. Strong growth driven by double-digit volume growth in Europe, Japan, and China. Volume doubled in the rest of the world due to Mounjaro's launch in new markets.
Dividends and Share Repurchases $1.3 billion in dividends and $1.5 billion in share repurchases.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Medicines: Launched Inluriyo, secured new indications for Omvoh and Jaypirca, and completed international rollouts of Mounjaro and Kisunla.
Clinical Trials: Generated positive data in over 25 Phase III trials, including for orforglipron and retatrutide. Started 14 new Phase III programs.
AI in Drug Discovery: Invested in AI with a new supercomputer and collaboration with NVIDIA to accelerate drug discovery.
Market Expansion: Entered new markets with Mounjaro and Kisunla, achieving incretin share market leadership outside the U.S.
Obesity Medicines Access: Agreement with U.S. government to provide obesity medicines at $50/month for insured Americans through Medicare and Medicaid.
Manufacturing Expansion: Built new manufacturing sites in the U.S. and Europe, increasing capacity and achieving 1.8x incretin dose production compared to 2024.
Financial Performance: 2025 revenue grew 45% to $65.2 billion, with Q4 revenue up 43%. EPS grew 86% to $24.21.
Business Development: Executed 39 transactions, adding clinical stage assets through acquisitions like Scorpion, Verve, and Ventyx.
Pipeline Growth: One of the largest clinical stage pipelines in company history, with 36 active Phase III programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pricing Pressures: The company expects price to be a drag on growth in the low to mid-teens in 2026, driven by U.S. government access agreements for obesity medicines, updated direct-to-patient pricing, and lower Medicaid prices for later life cycle medicines. Pricing outside the U.S. will also be impacted by inclusion of Mounjaro on China's National Reimbursement Drug List.
Regulatory and Market Access Challenges: Medicaid access for obesity medicines is expected to reduce in 2026 due to key states like California removing coverage, although some new states may add coverage in 2027. Additionally, the company anticipates challenges in securing Medicare access for obesity medicines, which is expected no later than July 1, 2026.
R&D and Pipeline Investment Risks: The company is scaling up R&D expenses in 2026 to support 36 active Phase III programs and new launches. This significant investment in innovation carries inherent risks, including potential delays or failures in clinical trials.
Manufacturing and Operational Costs: Gross margin is expected to be relatively stable to slightly down in 2026 due to price pressures and new facilities coming online, which may increase operational costs.
Competitive Pressures: The incretin analog market is growing, but competition is intensifying, particularly with the launch of oral GLP-1s, which could expand the addressable market but also increase competitive dynamics.
Economic and Global Market Risks: Revenue growth outside the U.S. is subject to economic conditions in key markets like Europe, Japan, and China, which could impact volume growth and overall performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: We expect revenue to be between $80 billion and $83 billion in 2026, representing a midpoint increase of 25% compared to 2025. Growth will be driven by key products, partially offset by lower realized prices.
Market Trends and Growth: The U.S. incretin analogs market is expected to continue its robust growth trajectory in 2026. The launch of oral GLP-1s is anticipated to expand the addressable market. Medicare access to obesity medicines is expected to become effective by July 1, 2026, while Medicaid access may see reductions in some states but expansions in others by 2027.
Product Launches and Pipeline: Orforglipron is expected to launch for chronic weight management in the U.S. during Q2 2026 and in most international markets by 2027. Retatrutide is expected to have six additional Phase III trial readouts in 2026, with potential applications for obesity, obstructive sleep apnea, and osteoarthritis of the knee. The company plans to initiate new Phase III programs for other molecules, including tersolisib and vepugratinib, in oncology.
R&D and Innovation: R&D expenses are expected to scale up in 2026, with 36 active Phase III programs and plans to initiate more. Investments will focus on maximizing the impact of potential new medicines, including incretins and other therapeutic areas.
Earnings and Margins: Non-GAAP performance margin is expected to be between 46% and 47.5%. Earnings per share are projected to be between $33.50 and $35, indicating strong top-line and bottom-line growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends distributed: $1.3 billion in dividends were distributed in 2025.
Share repurchases: $1.5 billion in share repurchases were conducted in 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are some metrics being tracked for the orforglipron launch?
A:Metrics include market expansion, patient satisfaction scores, and real-world efficacy. The company is optimistic about the competitiveness of the product profile and its potential to expand the market.
Q:Are there any accelerated pathways for orforglipron approvals outside the U.S.?
A:Most approvals are expected in the first half of 2027, with a few markets launching in late 2026. Some countries, like the UAE, may reference FDA approval for earlier launches.
Q:What are the expectations for international Mounjaro growth in 2026?
A:The company expects growth based on market expansion and patient activation for chronic weight management. They aim to gain reimbursement in more countries while maintaining pricing discipline.
Q:Why isn't the company investing in immunology as aggressively as in obesity?
A:The company is reinvesting proceeds from obesity into oncology, neuroscience, and immunology. They are focusing on promising science and combination therapies in immunology, with ongoing trials for incretins and other therapies.
Q:What is the impact of Medicare volume ramp on revenue guidance?
A:Medicare access is expected by July 1, with a bolus of patients transitioning from LillyDirect. The company anticipates gradual penetration and sees Medicare as a significant opportunity for anti-obesity medications.
Q:What is the potential for combination therapies with Zepbound in immunology or other areas?
A:The company is exploring combinations like Taltz and Zepbound for psoriasis and other immune diseases. They are also conducting trials for combinations in ulcerative colitis, Crohn's disease, and asthma.
Q:What are the pricing dynamics and price elasticity for obesity medications?
A:The company has seen affordability and predictable costs drive utilization. They are optimistic about the uptake of oral options and have set competitive entry prices for new launches.
Q:How important are obesity-related indications for long-term strategy?
A:The company sees growing evidence supporting the coverage of obesity medications for broader health outcomes. They are exploring new indications like stress urinary incontinence and hypertension.
Q:What are the long-term implications of cash pay for obesity medications?
A:The company is building consumer-centric platforms like LillyDirect to reduce friction and improve access. They see potential in scaling and evolving the consumer experience.
Q:What is the strategy for eloralintide development?
A:The company is exploring titration strategies and combinations with other mechanisms like GIP agonists. They aim to optimize efficacy with minimal titration.
Q:What are the similarities between the CMS obesity pilot and the Part D insulin program?
A:Both programs aim to reduce out-of-pocket costs and increase utilization. The obesity pilot is expected to expand the class and demonstrate cost savings for Medicare.
Q:Can the 2026 revenue guidance be achieved without orforglipron being a $5 billion product?
A:The guidance includes multiple factors like Medicare expansion, orforglipron launch, and international growth. Early data suggests the oral market is expanding rather than cannibalizing.
Q:What are the consumer analogs for obesity medications?
A:The company sees obesity medications as unique, with no direct analogs. They are leveraging learnings from other industries to improve consumer experience and access.
Q:How does the orforglipron launch compare to tirzepatide?
A:The orforglipron launch benefits from greater consumer and provider awareness. The company expects it to expand the market and bring new patients to therapy.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the long-term implications of cash pay dynamics and the potential cannibalization between oral and injectable obesity products. They also provided limited details on the specific metrics for orforglipron's success and the exact impact of Medicare volume ramp on revenue guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alzheimer disease
BRUIN CLL
CLL SLL
GIP GLP
GLP therapy
III pirtobrutinib
III program
III trial
Medicaid
NVIDIA
Participants
Phase III
Product Officer
RD
SLL patient
TRIUMPH
access obesity
adult
alpha
arthritis
brenipatide Phase
covalent BTK
generation
history
incretin
incretins
ixekizumab
knee
number people
obesity medicine
offering
orforglipron weight
patient breast
prescription market
reduction
retatrutide
submission orforglipron
tirzepatide
type diabetes
use disorder
LLY Transcript
Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Neutral5-28
Eli Lilly and Company (LLY) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates strong financial performance, with revenue growth and solid earnings projections. Product development is robust, with new launches and pipeline expansion. Market strategy is well-defined, focusing on Medicare activation and employer programs. Expenses are increasing due to R&D, but financial health appears strong with good margins. Shareholder return plans are not explicitly mentioned, but the overall sentiment from the Q&A supports a positive outlook. The combination of optimistic guidance, strategic market expansion, and innovative product launches suggests a likely positive stock price movement.
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
LLY Slides
LLY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
